Clinical Use of Herceptin Explored

[Lani]

" Trastuzumab MIGHT benefit women with early stage HER2+, estrogen- breast cancer and should be considered"
(where has he been? Virtually all adjuvant trials of herceptin, whether HERA, No. American combined trials, the TCH trials, and Fin Her trials came to the same conclusion-- isn't an ALMOST 50% reduction in recurrence , even if the absolute risk of recurrence may be a larger or smaller number (based on various clinical and immunohistochemical factors), which has proven to hold out over 4 years as the trial data has matured, worthy of of a word stronger than MIGHT?

He sounds like a representative of a national health service parsing his words trying to avoid giving an expensive drug to those it might benefit.

I don't think he has the data to support his statement regarding the "small", her2+ ER+ TUMORS WHICH WERE node negative, as they were not included in the studies. So more patients will be treated or denied treatment based on "but the New England Journal says"...

Sorry for more ranting and raving.